A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
Open Access
- 29 March 2004
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 2 (1) , 9
Abstract
The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific). Towards this goal, we adapted the IFN-γ ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype protein. After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells. These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets.Keywords
This publication has 17 references indexed in Scilit:
- Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced MelanomaJournal of Clinical Oncology, 2003
- Translational development of active immunotherapy for hematologic malignanciesSeminars in Oncology, 2003
- Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based VaccinesJournal of Clinical Oncology, 2002
- In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.2002
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreadingInternational Journal of Cancer, 2001
- Immunologic Monitoring of Clinical Trials in Patients with Cancer: TechnologyVersusCommon SenseImmunological Investigations, 2000
- Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.Proceedings of the National Academy of Sciences, 1995
- Endogenous antigen presentation by MHC class II moleculesImmunologic Research, 1994
- Class II MHC molecules can use the endogenous pathway of antigen presentationNature, 1990